Rapid Micro Biosystems, Inc. filed an 8-K on November 16, 2026, disclosing that it entered into an Agreement and Plan of Merger with Merck KGaA, Darmstadt, Germany, and its wholly owned subsidiary EMD Holdings NewCo II, Inc., under which a cash tender offer of $0.75 per share would be commenced for all outstanding shares of Company Common Stock.

Key Highlights

  • Offer Price: The tender offer is set at $0.75 per share in cash, without interest, for all issued and outstanding shares of Class A and Class B common stock, subject to any required tax withholding.
  • Acquirer: The Purchaser is EMD Holdings NewCo II, Inc., a Delaware corporation and a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany.
  • Minimum Condition: The Purchaser's obligation to accept shares is conditioned on tendered Class A Common Shares, together with those owned by Parent and affiliates, representing one more Class A Common Share than 50% of total Class A Common Shares issued and outstanding following consummation of the Offer plus any Pre-Funded Warrant Shares.
  • No Stockholder Vote Required: The Merger will be governed by Section 251(h) of the DGCL, and no stockholder vote is required to consummate the Merger.
  • Offer Expiration: The Offer will initially expire at one minute after 11:59 p.m. Eastern Time on the date that is 10 business days following commencement, subject to extension under certain circumstances.
  • Equity Award Treatment: Vested Company Options will be cancelled for a cash payment equal to the excess, if any, of the $0.75 Merger Consideration over the exercise price; unvested options will convert to Parent Cash-Based Option Awards on the same vesting schedule; options with exercise prices at or above $0.75 will be cancelled for no consideration.

Rapid Micro Biosystems Merger Agreement Terms and Transaction Structure

According to the filing, Rapid Micro Biosystems, Inc. (NASDAQ:RPID) entered into the Merger Agreement on November 16, 2026, with Merck KGaA, Darmstadt, Germany, acting as Parent, and EMD Holdings NewCo II, Inc. as Purchaser. The filing states that Purchaser will commence a cash tender offer to acquire all issued and outstanding shares of Class A common stock, $0.01 par value per share, and Class B common stock, $0.01 par value per share, at the Offer Price of $0.75 per share, without interest and subject to applicable tax withholding.

The filing discloses that following the consummation of the Offer, Purchaser will merge with and into the Company, with the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent. The Merger requires no separate stockholder vote, as it is governed by Section 251(h) of the Delaware General Corporation Law. At the effective time of the Merger, each share of Company Common Stock not otherwise excluded under the terms of the Merger Agreement will be converted into the right to receive $0.75 in cash, without interest and subject to withholding of taxes required by applicable law, the filing states.

Regarding equity awards, the filing specifies that vested restricted stock unit awards will be cancelled and converted into the right to receive cash equal to the total number of shares subject to such vested RSUs multiplied by $0.75, less applicable tax withholding. Unvested RSU awards will be converted into Parent Cash-Based RSU Awards representing a fixed time-based cash amount calculated on the same basis. The filing also lists customary closing conditions, including no Material Adverse Effect occurring since execution of the Merger Agreement, no prohibiting governmental orders, and satisfaction of representations, warranties, and covenants by the Company.

What Was Disclosed

Rapid Micro Biosystems disclosed entry into a Merger Agreement with Merck KGaA and EMD Holdings NewCo II, Inc. on November 16, 2026, providing for a $0.75 per share all-cash tender offer and subsequent merger requiring no stockholder vote under DGCL Section 251(h).